Core Points - Faircourt Asset Management Inc. announced a monthly distribution for the Faircourt Gold Income Corp. fund, with a distribution amount of $0.024 per share [1][2] - The ex-dividend date is set for November 28, 2025, with the record date also on November 28, 2025, and the payable date on December 12, 2025 [2] Company Information - Faircourt Asset Management Inc. serves as the Investment Advisor for Faircourt Gold Income Corp. [2] - The Faircourt Fund is traded on the CBOE under the symbol FGX [2] Additional Information - Investors should be aware of ongoing fees and expenses associated with owning units of an investment fund, and detailed information can be found in public filings [3]

Core Insights - Fountain Asset Corp. reported financial results for Q3 and the nine months ended September 30, 2025, highlighting significant gains and a strong financial position [1][6]. Q3 2025 Highlights - The company realized $1.48 million in gains from the sale of portfolio investments, benefiting from increased trading prices in the technology and mining sectors [4]. - Net assets were valued at $8.56 million or $0.13 per share, an increase from $5.51 million or $0.09 per share at the end of 2024, representing a 44% increase year to date on a per share basis [5][8]. - The net comprehensive loss was reduced to $0.03 million compared to a loss of $0.71 million in Q3 2024 [8]. - Total gains from investment activity amounted to $0.42 million, contrasting with losses of $0.43 million in Q3 2024 [8]. - Operating expenses were maintained at a low level of $0.14 million, down from $0.26 million in Q3 2024 [8]. Nine Months Ended September 30, 2025 Highlights - The company reported a net comprehensive income of $3.03 million, a significant turnaround from a net comprehensive loss of $1.65 million for the same period in 2024 [8]. - Total income from investment activity reached $4.07 million, compared to a total loss of $0.98 million for the nine months ended September 30, 2024 [8]. - Net realized gains on the sale of portfolio investments were $3.24 million, compared to net realized losses of $0.08 million in the prior year [8]. - Net unrealized gains on portfolio investments were $0.74 million, contrasting with net unrealized losses of $0.90 million for the same period in 2024 [8]. - Total expenses for the nine months were $1.02 million, up from $0.67 million in the previous year [8]. Company Overview - Fountain Asset Corp. operates as a merchant bank, providing equity financing, bridge loan services, and strategic financial consulting across various industries, including marijuana, oil & gas, mining, real estate, manufacturing, retail, financial services, and biotechnology [9].

Core Viewpoint - SC II Acquisition Corp. has announced the pricing of its initial public offering (IPO) of 15,000,000 units at a price of $10.00 per unit, with trading set to begin on November 26, 2025 [1] Company Overview - The Company is a blank check company formed to pursue a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses across any industry or geographical location [2] - The Company's sponsor is managed by Nukkleus Defense Technologies, Inc., a wholly-owned subsidiary of Nukkleus Inc, with Menny Shalom serving as the Chief Executive Officer and director [2] Offering Details - The IPO consists of 15,000,000 units, each comprising one Class A ordinary share and one right to receive one fifth (1/5) of a Class A ordinary share upon the completion of the initial business combination [1] - The offering is expected to close on November 28, 2025, subject to customary closing conditions [1] - D. Boral Capital is the sole book-running manager for the offering, with legal counsel provided by Ellenoff Grossman & Schole LLP and Appleby (Cayman) Ltd. [3] Additional Information - The Company has granted underwriters a 45-day option to purchase up to an additional 2,250,000 units at the IPO price to cover over-allotments [3] - A registration statement for the units and underlying securities became effective on November 25, 2025 [4]

Core Viewpoint - Ascendis Pharma A/S announced that the FDA has extended the PDUFA target action date for TransCon CNP by three months to February 28, 2026, due to a major amendment related to post-marketing requirements [1]. Group 1: FDA Interaction - The company has responded to all outstanding FDA requests, including a revised protocol for the post-marketing study, and is committed to working diligently with the FDA to finalize these elements [2]. - The extension of the PDUFA date indicates ongoing regulatory review and the need for additional information from the company [1]. Group 2: Company Overview - Ascendis Pharma is a global biopharmaceutical company focused on innovative therapies using its TransCon technology platform to address unmet medical needs [3]. - The company is headquartered in Copenhagen, Denmark, with additional facilities in Europe and the United States [3].

(2025-11-25) Reference is made to the stock exchange announcement made by Kitron ASA (the "Company") on 25 November 2025 regarding the successful private placement (the "Private Placement") where the Company allocated 17,000,000 new ordinary shares in the Company ("Offer Shares") at an offer price of NOK 57.25 per share (the "Offer Price"). In connection with the Private Placement, the following persons discharging managerial responsibilities were allocated Offer Shares in the Private Placement at the Offer ...

Core Points - Elme Communities has announced a special liquidating distribution of $14.67 per share, to be paid on January 7, 2026, to shareholders of record as of December 22, 2025 [1][2] - This distribution follows the completion of the sale of Elme's 19-property portfolio on November 12, 2025, and is part of a voluntary Plan of Sale and Liquidation approved by shareholders [2][6] Distribution Details - The Special Dividend is more than 25% of the price of Elme's common shares, leading to the NYSE advising that shares will trade with "due bills" from December 22, 2025, to January 7, 2026 [3][4] - Investors must hold shares through the payment date to be eligible for the Special Dividend, with the record date being used for due bill tracking [4][5] Tax Implications - Information regarding the expected U.S. federal income tax consequences of the Special Dividend and additional liquidating distributions is summarized in the Definitive Proxy filed on September 24, 2025 [6] Company Overview - Elme Communities is a multifamily real estate investment trust that owns and operates apartment homes in the Washington, DC metro and the Atlanta metro [7]

Core Viewpoint - Kitron ASA has successfully completed a private placement of up to 17,000,000 new ordinary shares, raising approximately NOK 973.25 million in gross proceeds to finance the acquisition of DeltaNordic AB and for general corporate purposes [2][3][4]. Group 1: Private Placement Details - The private placement involved the allocation of 17,000,000 Offer Shares at an offer price of NOK 57.25 each [3]. - Approximately NOK 814 million of the net proceeds will be used for the cash consideration in the acquisition of DeltaNordic AB, with excess funds directed towards general corporate purposes and strengthening the balance sheet [4]. - The Offer Shares will be issued based on the existing board authorization from the annual general meeting held on 24 April 2025 [5]. Group 2: Settlement and Registration - Notifications of allocation and payment instructions are expected to be distributed on 26 November 2025 [6]. - Settlement of the private placement will occur on a delivery versus payment basis, with expected registration of the share capital increase with the Norwegian Register of Business Enterprises around 27 November 2025 [7][8]. - Following the registration, the company's share capital will amount to NOK 21,640,285.90, divided into 216,402,859 shares [9]. Group 3: Shareholder Considerations - The private placement deviates from shareholders' pre-emptive rights, but the board believes it serves the common interest of the company and its shareholders by enabling efficient equity financing [10][11]. - The private placement will result in a limited dilution of existing shareholders, representing 8.5% new shares, with pricing set at a modest discount of approximately 4.9% to the last closing price [12]. Group 4: Management Participation - Key management personnel, including the CEO and CFO, were allocated Offer Shares in the private placement, indicating confidence in the company's future [17]. Group 5: Company Overview - Kitron ASA is a leading Scandinavian electronics manufacturing services company, with operations across multiple countries and revenues of EUR 647 million in 2024 [14].

Core Insights - Open Lending Corporation has appointed Abhijit "Abhi" Chaudhary to its Board of Directors as a Class I director, effective November 21, 2025, replacing Gene Yoon [1] - Mr. Chaudhary brings over 20 years of experience in product strategy for growth-oriented financial services, currently serving as Executive Vice President at Mastercard [2] - The CEO of Open Lending, Jessica Buss, expressed that Mr. Chaudhary's experience in scaling disruptive technology will provide valuable insights to the Board [3] Company Overview - Open Lending Corporation provides lending enablement and risk analytics solutions for financial institutions, focusing on loan analytics, risk-based pricing, risk modeling, and default insurance for auto lenders in the U.S. [4] - The company has been empowering financial institutions for 25 years to create profitable auto loan portfolios with reduced risk and increased rewards [4]

Core Insights - KOMZIFTI (ziftomenib) is the first and only once-daily oral menin inhibitor approved by the FDA for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation, now commercially available in the U.S. [1][2] - The drug has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines as a Category 2A recommended treatment option for this patient population [1][3] Company Overview - Kura Oncology, Inc. is a biopharmaceutical company focused on precision medicines for cancer treatment, with KOMZIFTI being a key product in its pipeline [19] - Kyowa Kirin Co., Ltd. is a global specialty pharmaceutical company with a long history in drug discovery and biotechnology innovation, collaborating with Kura on the commercialization of KOMZIFTI [20] Clinical Data - KOMZIFTI received full FDA approval on November 13, 2025, based on the KOMET-001 clinical trial, which demonstrated a 21.4% complete response (CR) or complete response with partial hematologic recovery (CRh) rate and a median duration of response of 5 months [2] - The clinical trial involved 112 patients with R/R AML and NPM1 mutation, with differentiation syndrome (DS) occurring in 26% of patients [8][14] Treatment Guidelines - The inclusion of KOMZIFTI in the NCCN Guidelines highlights its potential impact on patients with R/R NPM1-mutated AML and reflects the commitment to patient access [3] - KOMZIFTI is also being developed for front-line treatment of AML with various mutations, indicating its potential to benefit a broader patient population [5] Safety Information - KOMZIFTI has a boxed warning for differentiation syndrome, which can be fatal, and requires monitoring and management protocols [6][7] - Adverse reactions reported in clinical trials include serious reactions in 79% of patients, with the most common being infections and differentiation syndrome [14][16]

Core Viewpoint - Peoples Financial Corporation has declared a regular semi-annual cash dividend of $0.18 per common share, payable on December 12, 2025, to shareholders of record as of December 8, 2025 [1][2]. Company Overview - Founded in 1896, Peoples Financial Corporation has total assets of $758 million as of September 30, 2025, and operates 18 bank facilities along the Mississippi Gulf Coast [3]. - The Peoples Bank offers a comprehensive range of retail and commercial banking services, along with trust and investment services since 1936 [3]. Stock Information - Peoples Financial Corporation's common stock is listed on the OTCQX Best Market under the symbol PFBX [4].